{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:16:15Z","timestamp":1760296575111},"reference-count":28,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2008,6,28]],"date-time":"2008-06-28T00:00:00Z","timestamp":1214611200000},"content-version":"vor","delay-in-days":2492,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Med Austriaca"],"published-print":{"date-parts":[[2001,9]]},"abstract":"<jats:p><jats:bold>Zusammenfassung:<\/jats:bold> Die vorliegende \u00dcbersicht beschreibt die international anerkannten konservativen (vor allem medikament\u00f6sen) Ma\u00dfnahmen bei endokriner Orbitopathie. Diese m\u00fcssen sich dem Schweregrad der Erkrankung anpassen. Die Objektivierung desselben kann Schwierigkeiten machen, weshalb auf die Bedeutung von entsprechenden Erhebungssystemen, wie zum Beispiel dem Clinical Activity Score, eingegangen wird. Zun\u00e4chst steht die Sicherstellung einer normalen Schilddr\u00fcsenfunktion im Vordergrund. Bei milden Verlaufsformen reichen zus\u00e4tzliche supportive lokale Ma\u00dfnahmen. Bei schweren Verlaufsformen ist Kortison in verschiedenen Dosierungen und Applikationsarten das erste Mittel der Wahl. Die Ansprechrate der per os\u2010Therapie liegt international bei ca. 63\u2003%, jene der intraven\u00f6sen hochdosierten Bolustherapie bei ca. 77\u2003%. Als Alternative bzw. zur Kombination steht das ebenfalls nebenwirkungsreiche Immunsuppressivum Cyclosporin zur Verf\u00fcgung. Die Kombination mit Kortison scheint nach \u00fcbereinstimmenden Berichten der Kortison\u2010Monotherapie \u00fcberlegen. Eine weitere Alternative mit hochdosiertem, intraven\u00f6s verabreichten Immunglobulinen ist zwar nebenwirkungs\u00e4rmer bei gleicher Erfolgsrate wie die per os\u2010Kortisontherapie, birgt aber die Infektionsgefahr aller Plasmaderivate in sich und ist au\u00dferdem extrem teuer. Abschlie\u00dfend werden noch neuere Therapieversuche mit Immunmodulatoren wie Pentoxifyllin oder Methotrexat, welche bisher nur an wenigen Patienten mit schweren Verlaufsformen \u2013 da allerdings mit eindrucksvollem Erfolg \u2013 erprobt worden sind, vorgestellt.<\/jats:p>","DOI":"10.1046\/j.1563-2571.2001.01022.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T01:52:24Z","timestamp":1047347544000},"page":"93-96","source":"Crossref","is-referenced-by-count":3,"title":["Konservative Therapie bei endokriner Orbitopathie: \u201eState of the Art\u201d"],"prefix":"10.1111","volume":"28","author":[{"given":"M.","family":"Weissel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,6,28]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"13","article-title":"Highdose intravenous immunoglobulin treatment in Graves' ophtalmopathy","volume":"126","author":"Antonelli A","year":"1992","journal-title":"Acta endocrinol"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-978919"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.82.6.9995"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0950-351X(97)80738-0"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-129-8-199810150-00010"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1210\/er.21.2.168"},{"key":"e_1_2_6_8_2","first-page":"69","article-title":"Cortisone in exophtalmos. Report on a therapeutic trial of cortisone and corticotropin in exophtalmic ophtalmoplegia by a panel appointed by the medical research council","volume":"1","author":"Brain R","year":"1955","journal-title":"Lancet"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(63)90087-1"},{"key":"e_1_2_6_10_2","first-page":"Abstract","article-title":"Methotrexate in the treatment of refractory Graves' disease. 12th International Thyroid Congress, October 22 \u2013 27, 2000. Kyoto, Japan","volume":"47","author":"Heufelder AE","year":"2000","journal-title":"Endocrine J"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.1996.d01-854.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.1986.tb01016.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1563-2571.2001.01020.x"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1987.tb00836.x"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.73.8.639"},{"key":"e_1_2_6_16_2","first-page":"513","article-title":"Treatment of Graves' ophtalmopathy with high dose intravenous methylprednisolone pulse therapy","volume":"116","author":"Nagayama Y","year":"1987","journal-title":"Acta endocrinol (Kbh)"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1995.tb02597.x"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.1992.2.235"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198911163212002"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)92001-A"},{"key":"e_1_2_6_21_2","first-page":"185","article-title":"Amelioration of eye changes of Graves' ophtalmopathy by achieving euthyroidism","volume":"121","author":"Prummel MF","year":"1989","journal-title":"Acta endocrinol"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.150.5.1098"},{"key":"e_1_2_6_23_2","first-page":"109","article-title":"Highdose intravenous therapy with 7S immunoglobulins in autoimmune endocrine ophtalmopathy","volume":"14","author":"Seppel T Schlaghecke R","year":"1996","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI111642"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(83)90514-7"},{"key":"e_1_2_6_26_2","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1089\/thy.2000.10.521","article-title":"Fatal liver failure after highdose glucocorticoid pulse therapy in a patient with severe thyroid eye disease","volume":"10","author":"Weissel M","year":"2000","journal-title":"Thyroid"},{"key":"e_1_2_6_27_2","first-page":"9","article-title":"Kombinierte Therapie mit Cyclosporin A und Kortison bei der endokrinen Orbitopathie des Morbus Basedow: erfolgreicher Einsatz bei der kompressiven Optikusneuropathie","volume":"20","author":"Weissel M","year":"1993","journal-title":"Acta med Austriaca"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-29-7-982"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.86.2.501"}],"container-title":["Acta Medica Austriaca"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1563-2571.2001.01022.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1563-2571.2001.01022.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T22:04:40Z","timestamp":1697493880000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1563-2571.2001.01022.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,9]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2001,9]]}},"alternative-id":["10.1046\/j.1563-2571.2001.01022.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1563-2571.2001.01022.x","archive":["Portico"],"relation":{},"ISSN":["0303-8173","1563-2571"],"issn-type":[{"value":"0303-8173","type":"print"},{"value":"1563-2571","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,9]]}}}